Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells

S. Avvakumova, L. Pandolfi, E. Soprano, L. Moretto, M. Bellini, E. Galbiati, M. A. Rizzuto, M. Colombo, R. Allevi, F. Corsi, A. Sánchez Iglesias, D. Prosperi

Research output: Contribution to journalArticle

Abstract

The efficient targeting of cancer cells depends on the success of obtaining the active targeting of overexpressed receptors. A very accurate design of nanoconjugates should be done via the selection of the conjugation strategy to achieve effective targeted nanoconjugates. Here, we present a detailed study of cetuximab-conjugated nonspherical gold nanocages for the active targeting of triple-negative breast cancer cells, including MDA-MB-231 and MDA-MB-468. A few different general strategies were selected for monoclonal antibody conjugation to the nanoparticle surface. By varying the bioconjugation conditions, including antibody orientation or the presence of a polymeric spacer or recombinant protein biolinker, we demonstrate the importance of a rational design of nanoconjugates. A quantitative study of gold content via ICP-AES allowed us to compare the effectiveness of cellular uptake as a function of the conjugation strategy and confirmed the active nature of nanoparticle internalization in cancer cells via epidermal growth factor receptor recognition, corroborating the importance of the rational design of nanomaterials for nanomedicine.

Original languageEnglish
Pages (from-to)3626-3638
Number of pages13
JournalNanoscale Advances
Volume1
Issue number9
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Nanoconjugates
conjugation
breast
Gold
multiple docking adapters
cancer
Cells
gold
antibodies
Nanoparticles
Medical nanotechnology
Recombinant proteins
nanoparticles
Monoclonal antibodies
Recombinant Proteins
Epidermal Growth Factor Receptor
Nanostructured materials
Antibodies
spacers
Monoclonal Antibodies

ASJC Scopus subject areas

  • Engineering(all)
  • Bioengineering
  • Atomic and Molecular Physics, and Optics
  • Materials Science(all)
  • Chemistry(all)

Cite this

Avvakumova, S., Pandolfi, L., Soprano, E., Moretto, L., Bellini, M., Galbiati, E., ... Prosperi, D. (2019). Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells. Nanoscale Advances, 1(9), 3626-3638. https://doi.org/10.1039/c9na00241c

Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells. / Avvakumova, S.; Pandolfi, L.; Soprano, E.; Moretto, L.; Bellini, M.; Galbiati, E.; Rizzuto, M. A.; Colombo, M.; Allevi, R.; Corsi, F.; Sánchez Iglesias, A.; Prosperi, D.

In: Nanoscale Advances, Vol. 1, No. 9, 01.01.2019, p. 3626-3638.

Research output: Contribution to journalArticle

Avvakumova, S, Pandolfi, L, Soprano, E, Moretto, L, Bellini, M, Galbiati, E, Rizzuto, MA, Colombo, M, Allevi, R, Corsi, F, Sánchez Iglesias, A & Prosperi, D 2019, 'Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells', Nanoscale Advances, vol. 1, no. 9, pp. 3626-3638. https://doi.org/10.1039/c9na00241c
Avvakumova, S. ; Pandolfi, L. ; Soprano, E. ; Moretto, L. ; Bellini, M. ; Galbiati, E. ; Rizzuto, M. A. ; Colombo, M. ; Allevi, R. ; Corsi, F. ; Sánchez Iglesias, A. ; Prosperi, D. / Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells. In: Nanoscale Advances. 2019 ; Vol. 1, No. 9. pp. 3626-3638.
@article{7fab2068e4a6475ea21d9daf8aad9841,
title = "Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells",
abstract = "The efficient targeting of cancer cells depends on the success of obtaining the active targeting of overexpressed receptors. A very accurate design of nanoconjugates should be done via the selection of the conjugation strategy to achieve effective targeted nanoconjugates. Here, we present a detailed study of cetuximab-conjugated nonspherical gold nanocages for the active targeting of triple-negative breast cancer cells, including MDA-MB-231 and MDA-MB-468. A few different general strategies were selected for monoclonal antibody conjugation to the nanoparticle surface. By varying the bioconjugation conditions, including antibody orientation or the presence of a polymeric spacer or recombinant protein biolinker, we demonstrate the importance of a rational design of nanoconjugates. A quantitative study of gold content via ICP-AES allowed us to compare the effectiveness of cellular uptake as a function of the conjugation strategy and confirmed the active nature of nanoparticle internalization in cancer cells via epidermal growth factor receptor recognition, corroborating the importance of the rational design of nanomaterials for nanomedicine.",
author = "S. Avvakumova and L. Pandolfi and E. Soprano and L. Moretto and M. Bellini and E. Galbiati and Rizzuto, {M. A.} and M. Colombo and R. Allevi and F. Corsi and {S{\'a}nchez Iglesias}, A. and D. Prosperi",
year = "2019",
month = "1",
day = "1",
doi = "10.1039/c9na00241c",
language = "English",
volume = "1",
pages = "3626--3638",
journal = "Nanoscale Advances",
issn = "2516-0230",
number = "9",

}

TY - JOUR

T1 - Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells

AU - Avvakumova, S.

AU - Pandolfi, L.

AU - Soprano, E.

AU - Moretto, L.

AU - Bellini, M.

AU - Galbiati, E.

AU - Rizzuto, M. A.

AU - Colombo, M.

AU - Allevi, R.

AU - Corsi, F.

AU - Sánchez Iglesias, A.

AU - Prosperi, D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The efficient targeting of cancer cells depends on the success of obtaining the active targeting of overexpressed receptors. A very accurate design of nanoconjugates should be done via the selection of the conjugation strategy to achieve effective targeted nanoconjugates. Here, we present a detailed study of cetuximab-conjugated nonspherical gold nanocages for the active targeting of triple-negative breast cancer cells, including MDA-MB-231 and MDA-MB-468. A few different general strategies were selected for monoclonal antibody conjugation to the nanoparticle surface. By varying the bioconjugation conditions, including antibody orientation or the presence of a polymeric spacer or recombinant protein biolinker, we demonstrate the importance of a rational design of nanoconjugates. A quantitative study of gold content via ICP-AES allowed us to compare the effectiveness of cellular uptake as a function of the conjugation strategy and confirmed the active nature of nanoparticle internalization in cancer cells via epidermal growth factor receptor recognition, corroborating the importance of the rational design of nanomaterials for nanomedicine.

AB - The efficient targeting of cancer cells depends on the success of obtaining the active targeting of overexpressed receptors. A very accurate design of nanoconjugates should be done via the selection of the conjugation strategy to achieve effective targeted nanoconjugates. Here, we present a detailed study of cetuximab-conjugated nonspherical gold nanocages for the active targeting of triple-negative breast cancer cells, including MDA-MB-231 and MDA-MB-468. A few different general strategies were selected for monoclonal antibody conjugation to the nanoparticle surface. By varying the bioconjugation conditions, including antibody orientation or the presence of a polymeric spacer or recombinant protein biolinker, we demonstrate the importance of a rational design of nanoconjugates. A quantitative study of gold content via ICP-AES allowed us to compare the effectiveness of cellular uptake as a function of the conjugation strategy and confirmed the active nature of nanoparticle internalization in cancer cells via epidermal growth factor receptor recognition, corroborating the importance of the rational design of nanomaterials for nanomedicine.

UR - http://www.scopus.com/inward/record.url?scp=85072285349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072285349&partnerID=8YFLogxK

U2 - 10.1039/c9na00241c

DO - 10.1039/c9na00241c

M3 - Article

AN - SCOPUS:85072285349

VL - 1

SP - 3626

EP - 3638

JO - Nanoscale Advances

JF - Nanoscale Advances

SN - 2516-0230

IS - 9

ER -